Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Burkitt lymphoma is a highly aggressive B-cell lymphoma characterized by the rapid proliferation of malignant B lymphocytes. According to Guoqian Ma et al. (2025), an estimated 4,083 incident Burkitt lymphoma cases occurred globally in 2021, with an incidence rate of 0.20 per 100,000 population. According to Burkitt lymphoma epidemiology forecast by Expert Market Research, the disease burden is expected to evolve with improving diagnosis and treatment, supporting continued advances in disease management.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Burkitt Lymphoma – Number of Cases by Year

Read more about this report - Request a Free Sample

Burkitt Lymphoma Epidemiology Forecast Report Coverage

Expert Market Research's “Burkitt Lymphoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Burkitt lymphoma. It projects the future incidence and prevalence rates of Burkitt lymphoma cases across various populations. The study covers age, gender, and type as major determinants of the Burkitt lymphoma population. The report highlights patterns in the prevalence of Burkitt lymphoma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Burkitt lymphoma in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Burkitt Lymphoma Understanding: Disease Overview

Burkitt lymphoma is a highly aggressive form of non-Hodgkin lymphoma that develops from mature B lymphocytes. It is characterized by an extremely rapid cell proliferation rate and often presents as a rapidly enlarging tumor involving the abdomen, lymph nodes, bone marrow, or central nervous system. The disease is strongly associated with chromosomal translocations involving the MYC gene, which drives uncontrolled cell growth. Burkitt lymphoma is classified into three major types: endemic, sporadic, and immunodeficiency-associated, each differing in geographic distribution, underlying risk factors, and clinical presentation.

Key Report Insights

Parameter

Insight

Largest Patient Pool

India

Fastest Growing Region

India

High-Risk Population

Children, adolescents, immunocompromised individuals, and people living with Human Immunodeficiency Virus (HIV).

Key Diagnostic Method

Histopathological examination with immunophenotyping and fluorescence in situ hybridization (FISH) for MYC rearrangement.

Major Risk Factor

Epstein–Barr virus infection and immunodeficiency.

Major gap in the market

Delayed diagnosis and limited access to advanced molecular diagnostic testing.

Burkitt Lymphoma Epidemiology Perspective

The Burkitt lymphoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Burkitt lymphoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Burkitt lymphoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

As per Guoqian Ma et al., 2025, Burkitt lymphoma accounted for 4,083 incident cases globally in 2021 (95% uncertainty interval: 2,688–5,171), with a global incidence rate of 0.20 per 100,000, compared with 0.16 per 100,000 in 1990. Based on findings by Chengyun Dou et al., 2025, there were 19,072 incident Burkitt lymphoma cases globally in 2021, representing a 207% increase from 1990 to 2021, reflecting the rising global disease burden.

Gender-Specific Cases of the Disease

According to Radiopaedia, Burkitt lymphoma demonstrates a strong male predominance, with a male-to-female ratio of 4:1 in childhood cases. As highlighted by The Leukaemia Foundation, males are four times more likely to develop Burkitt lymphoma than females. Reported by Chengyun Dou et al., 2025, males consistently experienced higher incidence and mortality than females across all age groups.

Age-Specific Cases of the Disease

As noted by Radiopaedia, Burkitt lymphoma is the most common childhood non-Hodgkin lymphoma, accounting for 40% of childhood non-Hodgkin lymphoma, with a median age of 8 years, while representing only 1–2% of adult lymphomas. According to The Leukaemia Foundation, approximately 30% of non-Hodgkin lymphoma cases among children aged 5–10 years are Burkitt lymphoma, whereas adults 30–40 years of age are also commonly affected. Chengyun Dou et al., 2025 further reported that the 0–14 years and 50–74 years age groups accounted for the highest incidence and mortality.

Ethnicity-Wise Cases of the Disease

As per The Leukaemia Foundation, sporadic Burkitt lymphoma is most commonly observed in individuals of European descent, whereas endemic Burkitt lymphoma predominantly affects children in Africa. Radiopaedia also reported that endemic Burkitt lymphoma occurs at rates up to 50 times higher in parts of Africa than in the United States, demonstrating substantial geographic and population-based variation.

Mortality and Survival Analysis of the Disease

According to Guoqian Ma et al., 2025, the low sociodemographic index region reported the highest mortality rate of 0.43 per 100,000, with the global mortality rate projected to decline to 0.10 per 100,000 by 2035. Reported by Chengyun Dou et al., 2025, Burkitt lymphoma-associated deaths increased from 3,843 in 1990 to 6,525 in 2021. As documented by Clare M. Wieland et al., 2024, patients with HIV-associated Burkitt lymphoma had a 55% higher risk of death between 3 and 60 months after diagnosis than patients without HIV.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Sporadic Burkitt Lymphoma

According to The Leukaemia Foundation, sporadic Burkitt lymphoma is the predominant subtype outside endemic regions, particularly among people of European descent, and accounts for around 30% of childhood non-Hodgkin lymphoma cases. In India, Akhil Rajendra et al., 2025 reported that sporadic Burkitt lymphoma is among the major disease subtypes.

Endemic Burkitt Lymphoma

As highlighted by The Leukaemia Foundation, endemic Burkitt lymphoma primarily affects children in Africa and is closely associated with Epstein–Barr virus infection. Radiopaedia reported that incidence in endemic African regions is up to 50 times higher than in the United States, reflecting its substantial regional burden.

Immunodeficiency-Related Burkitt Lymphoma

As per The Leukaemia Foundation, immunodeficiency-related Burkitt lymphoma mainly affects individuals with human immunodeficiency virus or other immunodeficiency conditions. Reported by Clare M. Wieland et al., 2024, Burkitt lymphoma accounts for 10–35% of AIDS-defining lymphomas, while Akhil Rajendra et al., 2025 identified this subtype as one of the predominant forms reported in India.

Burkitt Lymphoma – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Burkitt Lymphoma Epidemiology

The Burkitt Lymphoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

As documented by Clare M. Wieland et al., 2024, approximately 1.2 million people are living with human immunodeficiency virus in the United States, and Burkitt lymphoma accounts for 10–35% of AIDS-defining lymphomas. According to Chengyun Dou et al., 2025, the contribution of high body mass index to the Burkitt lymphoma burden reached 0.06 disability-adjusted life-years in the United States.

Germany

As noted by Zentrum für Krebsregisterdaten, Burkitt lymphoma accounted for approximately 6.2% of non-Hodgkin lymphoma cases within the reported lymphoma population, reflecting its contribution to the national lymphoma burden.

France

Burkitt lymphoma contributes to the overall burden of non-Hodgkin lymphoma in France, with epidemiological assessments focusing on disease occurrence, demographic distribution, and long-term population trends to support healthcare planning and disease surveillance.

Italy

Epidemiological monitoring in Italy evaluates Burkitt lymphoma through incidence patterns, demographic characteristics, and disease burden, supporting continued improvements in diagnosis, surveillance, and healthcare resource allocation.

Spain

Burkitt lymphoma remains an uncommon subtype of non-Hodgkin lymphoma in Spain, with epidemiological evaluations emphasizing incidence patterns, demographic characteristics, and overall disease burden across the population.

United Kingdom

Based on findings by Chengyun Dou et al., 2025, the United Kingdom recorded a disability-adjusted life-year contribution of 0.05 from high body mass index to the Burkitt lymphoma burden. Continued epidemiological surveillance monitors disease incidence and mortality trends across the country.

Japan

Burkitt lymphoma remains a rare lymphoma subtype in Japan, where epidemiological assessments focus on disease incidence, age distribution, and long-term burden to support effective healthcare planning and patient management.

India

According to Akhil Rajendra et al., 2025, sporadic and human immunodeficiency virus-related Burkitt lymphoma are the predominant subtypes reported in India. As per Chengyun Dou et al., 2025, the contribution of high body mass index to the Burkitt lymphoma burden was relatively low, at 0.005 disability-adjusted life-years.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Despite advances in Burkitt lymphoma diagnosis and treatment, substantial gaps remain across regional epidemiology landscapes. Delayed disease recognition, inadequate access to molecular diagnostic technologies, and disparities in specialized oncology care continue to affect timely diagnosis and patient outcomes, particularly in developing regions. Emerging opportunities include expanding genomic testing capabilities, strengthening early referral pathways, improving disease surveillance systems, and increasing access to standardized treatment protocols. Greater investment in precision diagnostics, biomarker-based risk stratification, and collaborative research initiatives is expected to enhance disease management and support more accurate epidemiological assessments.

Burkitt Lymphoma: Treatment Overview

Burkitt lymphoma treatment primarily involves intensive combination chemotherapy regimens, which have significantly improved survival outcomes when initiated promptly. Multi-agent chemotherapy protocols are often combined with central nervous system prophylaxis because of the high risk of disease spread to the brain and spinal cord. Targeted therapies, such as anti-CD20 monoclonal antibodies, may be incorporated for eligible patients to improve treatment response. Supportive care, including tumor lysis syndrome prevention, infection management, and hematologic monitoring, is essential to minimize treatment-related complications and optimize patient outcomes.

Key Questions Answered

  • What is the current and projected burden of Burkitt lymphoma across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Burkitt lymphoma patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Burkitt lymphoma across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Burkitt lymphoma across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Burkitt lymphoma across the 8 major markets?
  • How do major comorbidities and risk factors influence Burkitt lymphoma epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Burkitt lymphoma across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Burkitt lymphoma landscape across the 8 major markets?
  • Which therapeutic areas linked to Burkitt lymphoma are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Burkitt lymphoma epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Burkitt lymphoma epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Burkitt lymphoma across the 8 major markets?

Scope of the Burkitt Lymphoma Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Burkitt lymphoma based on several factors.
  • Burkitt Lymphoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Burkitt lymphoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report

Non-Hodgkin’s Lymphoma Pipeline Analysis Report

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us